🔹 Revenue: $157.4M (Est. $146.74M) 🟢; +38% YoY
🔹 Adj. EPS: $0.92 (Est. $0.45) 🟢
🔹 Gross Margin: 61% (flat YoY)
FY25 Guidance (Raised):
🔹 Revenue: $585M–$605M (Est. $582M) 🟢
Other Q2 Metrics:
🔹 Net Income: $34.9M; UP +186% YoY
🔹 Oper Expenses: $60.0M (vs. $56.8M YoY); includes $9.0M stock comp
🔹 Cash: $400.6M (as of June 30, 2025)
Key Business Updates:
🔹 IDE approval received from FDA for Next-Gen OCS™ Lung trial
🔹 Launched OCS NOP digital ecosystem: NOP ACCESS™
🔹 Continued expansion of aviation fleet driving growth in NOP
CEO Commentary:
🔸 “Another strong quarter marked by 38% revenue growth and increased profitability.” – CEO Waleed Hassanein
🔸 “We remain laser focused on our 2028 goal of 10,000 U.S. NOP transplants.”
🔸 “Investing now for multiple future growth waves across transplant therapy.”
